title: A price for cost-effectiveness: implications for recombinant human activated protein C (rhAPC).
authors.forename: Donald B
authors.initials: DB
authors.lastname: Chalfin
authors.forename: Daniel
authors.initials: D
authors.lastname: Teres
authors.forename: John
authors.initials: J
authors.lastname: Rapoport
mesh_terms: D000890:Anti-Infective Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D017048:Health Care Costs; D006801:Humans; D011486:Protein C / Q000191:economics* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000191:economics* / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy*; D014481:United States
chemical_list: D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated